Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
31.46
-0.49 (-1.55%)
At close: Aug 11, 2025, 4:00 PM
31.50
+0.04 (0.13%)
After-hours: Aug 11, 2025, 7:03 PM EDT
G1 Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
128
Market Cap
3.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 33.19M | 14.38M | 76.41% |
Dec 31, 2021 | 18.82M | 3.41M | 22.16% |
Dec 31, 2020 | 15.40M | -5.09M | -24.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SRRK News
- 4 days ago - Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress - Business Wire
- 21 days ago - Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 - Business Wire
- 24 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial - Business Wire
- 7 weeks ago - Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
- 7 weeks ago - Scholar Rock Shares Jump on Positive Results from Weight Loss Trial - Market Watch
- 7 weeks ago - Scholar Rock's drug helps preserve lean mass in mid-stage trial - Reuters